Aberrant Splicing in Cancer: Mediators of Malignant Progression through an Imperfect Splice Program Shift

Abstract

Although the efforts to understand the genetic basis of cancer allowed advances in diagnosis and therapy, little is known about other molecular bases. Splicing is a key event in gene expression, controlling the excision of introns decoded inside genes and being responsible for 80% of the proteome amplification through events of alternative splicing. Growing data from the last decade point to deregulation of splicing events as crucial in carcinogenesis and tumor progression. Several alterations in splicing events were observed in cancer, caused by either missexpression of or detrimental mutations in some splicing factors, and appear to be critical in carcinogenesis and key events during tumor progression. Notwithstanding, it is difficult to determine whether it is a cause or consequence of cancer and/or tumorigenesis. Most reviews focus on the generated isoforms of deregulated splicing pattern, while others mainly summarize deregulated splicing factors observed in cancer. In this review, events associated with carcinogenesis and tumor progression mainly, and epithelial-to-mesenchymal transition, which is also implicated in alternative splicing regulation, will be progressively discussed in the light of a new perspective, suggesting that splicing deregulation mediates cell reprogramming in tumor progression by an imperfect shift of the splice program.

p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure–Function Continuum Concept

“…In fact, for them (as well as many other proteins), it was shown that an aberration in any part of the cellular machinery generating proteoforms (which are the basis of the existence of the protein structure–function continuum) might have some disastrous consequences [194]. For example, it is now recognized that deregulation of splicing events (via mutations or misexpression of some splicing factors) is a crucial trigger and initiator of carcinogenesis and tumor progression [257]. Obviously, this list can be further extended to include almost any protein.…”

Identification and validation of alternative splicing isoforms as novel biomarker candidates in hepatocellular carcinoma

“…Thus, one important aim of the present study was to identify biomarkers for predicting therapeutic response and prognosis, which may provide a deeper understanding of the tumor biology (1,2). To date, numerous molecular events, including those at the epigenetic, pre-transcriptional, transcriptional, translational and post-translational levels, have been identified and validated as important prognostic biomarkers (3), such as the Ki-67 protein and TP53 gene mutations. However, the functional significance of cancer-specific alternative splicing (AS) events is largely unexplored.…”

“…In the last decade, growing data has indicated that the dysregulation of AS is a crucial event in carcinogenesis and tumor progression (3,(7)(8)(9). Genes with aberrant AS events are involved in almost every aspect of cancer, including…”

RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions

“…This strategy is potentially an attractive one in cancer as well, because it is well known that tumors often have misregulated splicing that could potentially be corrected by this approach. 88 …”